-
Posted by
Two Blokes Apr 25 -
Filed in
Stock
-
2 views
AbbVie Inc. beat first-quarter revenue and EPS estimates and raised the full-year EPS guidance by $0.10 and revenue guidance by $700 million. Skyrizi and Rinvoq drove the ABBV Q1 beat with exceptional growth, leading to increased full-year revenue net sales guidance for both drugs. The immunology and neuroscience segments showed robust performance, supporting a bullish outlook, while Humira, the aesthetics, and eye care segments remain weak spots.
